GR3036560T3 - Bicyclic substituted hexahydrobenz(e)isoindole alpha-1- adrenergic antagonists - Google Patents
Bicyclic substituted hexahydrobenz(e)isoindole alpha-1- adrenergic antagonistsInfo
- Publication number
- GR3036560T3 GR3036560T3 GR20010401414T GR20010401414T GR3036560T3 GR 3036560 T3 GR3036560 T3 GR 3036560T3 GR 20010401414 T GR20010401414 T GR 20010401414T GR 20010401414 T GR20010401414 T GR 20010401414T GR 3036560 T3 GR3036560 T3 GR 3036560T3
- Authority
- GR
- Greece
- Prior art keywords
- alpha
- adrenergic antagonists
- bicyclic substituted
- isoindole
- substituted hexahydrobenz
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/379,823 US5521181A (en) | 1995-01-27 | 1995-01-27 | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
| US08/465,476 US5792767A (en) | 1995-01-27 | 1995-06-05 | Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists |
| PCT/US1996/000178 WO1996022991A1 (en) | 1995-01-27 | 1996-01-11 | Bicyclic substituted hexahydrobenz[e]isoindole alpha-1- adrenergic antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3036560T3 true GR3036560T3 (en) | 2001-12-31 |
Family
ID=27008783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20010401414T GR3036560T3 (en) | 1995-01-27 | 2001-09-06 | Bicyclic substituted hexahydrobenz(e)isoindole alpha-1- adrenergic antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5792767A (el) |
| EP (1) | EP0805812B1 (el) |
| JP (1) | JPH11501616A (el) |
| KR (1) | KR19980701780A (el) |
| AT (1) | ATE202107T1 (el) |
| AU (1) | AU694611B2 (el) |
| CA (1) | CA2210966A1 (el) |
| DE (1) | DE69613347T2 (el) |
| DK (1) | DK0805812T3 (el) |
| ES (1) | ES2159721T3 (el) |
| GR (1) | GR3036560T3 (el) |
| IL (1) | IL116406A0 (el) |
| MX (1) | MX9705675A (el) |
| PT (1) | PT805812E (el) |
| WO (1) | WO1996022991A1 (el) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133275A (en) * | 1998-05-06 | 2000-10-17 | Abbott Laboratories | 3-phenylpyrrolidine alpha-1 adrenergic compounds |
| US6930101B1 (en) | 1999-05-17 | 2005-08-16 | The Regents Of The University Of California | Thiazolopyrimidines useful as TNFα inhibitors |
| HN2000000051A (es) * | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
| US8889112B2 (en) * | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US20020082288A1 (en) * | 1999-09-16 | 2002-06-27 | Gerald Horn | Ophthalmic formulations comprising an imidazoline |
| US6730065B1 (en) | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
| EP1277741A4 (en) | 2000-04-28 | 2003-05-07 | Tanabe Seiyaku Co | CYCLE CONNECTIONS |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| US20060211753A1 (en) * | 2000-11-03 | 2006-09-21 | Ocularis Pharma, Inc. | Method and composition which reduces stimulation of muscles which dilate the eye |
| WO2002064598A1 (en) | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| NZ527741A (en) | 2001-02-26 | 2005-02-25 | Tanabe Seiyaku Co | Pyridopyrimidine or naphthyridine derivative |
| US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
| US7497827B2 (en) | 2004-07-13 | 2009-03-03 | Dexcom, Inc. | Transcutaneous analyte sensor |
| CA2492387A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| UA89201C2 (ru) | 2004-08-18 | 2010-01-11 | Астразенека Аб | Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| US20100291151A1 (en) * | 2009-04-21 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| US9089560B2 (en) | 2013-02-01 | 2015-07-28 | Ocularis Pharma, Llc | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
| CA2899339C (en) | 2013-02-01 | 2021-07-06 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
| JP2022505950A (ja) | 2018-10-26 | 2022-01-14 | オキュフィア・ファーマ・インコーポレイテッド | 老眼、散瞳、および他の眼障害の治療のための方法および組成物 |
| JP7539391B2 (ja) * | 2019-08-29 | 2024-08-23 | 住友化学株式会社 | イソシアナート化合物の製造方法 |
| CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU560459B2 (en) * | 1982-06-01 | 1987-04-09 | Abbott Laboratories | Tetrahydro-benzo(e) isoindolines |
| ES2059828T3 (es) * | 1988-01-15 | 1994-11-16 | Abbott Lab | Un procedimiento para la preparacion de un compuesto. |
| ES2059570T3 (es) * | 1988-01-15 | 1994-11-16 | Abbott Lab | 1-aminometil-1,2,3,4-tetrahidronaftalenos e -indanos. |
| US5420128A (en) * | 1990-10-09 | 1995-05-30 | Otsuka Pharmaceutical Co., Ltd. | Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor |
| US5158953A (en) * | 1991-08-13 | 1992-10-27 | National Science Council | 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof |
| US5288749A (en) * | 1991-12-20 | 1994-02-22 | Abbott Laboratories | Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors |
| US5403847A (en) * | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
| US5521181A (en) * | 1995-01-27 | 1996-05-28 | Abbott Laboratories | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
-
1995
- 1995-06-05 US US08/465,476 patent/US5792767A/en not_active Expired - Fee Related
-
1996
- 1996-01-11 KR KR1019970705177A patent/KR19980701780A/ko active IP Right Grant
- 1996-01-11 AT AT96903364T patent/ATE202107T1/de not_active IP Right Cessation
- 1996-01-11 EP EP96903364A patent/EP0805812B1/en not_active Expired - Lifetime
- 1996-01-11 DK DK96903364T patent/DK0805812T3/da active
- 1996-01-11 PT PT96903364T patent/PT805812E/pt unknown
- 1996-01-11 ES ES96903364T patent/ES2159721T3/es not_active Expired - Lifetime
- 1996-01-11 CA CA002210966A patent/CA2210966A1/en not_active Abandoned
- 1996-01-11 MX MX9705675A patent/MX9705675A/es unknown
- 1996-01-11 JP JP8522872A patent/JPH11501616A/ja active Pending
- 1996-01-11 WO PCT/US1996/000178 patent/WO1996022991A1/en active IP Right Grant
- 1996-01-11 AU AU47473/96A patent/AU694611B2/en not_active Ceased
- 1996-01-11 DE DE69613347T patent/DE69613347T2/de not_active Expired - Fee Related
- 1996-12-15 IL IL11640695A patent/IL116406A0/xx unknown
-
2001
- 2001-09-06 GR GR20010401414T patent/GR3036560T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE202107T1 (de) | 2001-06-15 |
| MX9705675A (es) | 1997-10-31 |
| IL116406A0 (en) | 1996-12-15 |
| AU4747396A (en) | 1996-08-14 |
| PT805812E (pt) | 2001-11-30 |
| DE69613347T2 (de) | 2002-04-18 |
| US5792767A (en) | 1998-08-11 |
| DE69613347D1 (de) | 2001-07-19 |
| ES2159721T3 (es) | 2001-10-16 |
| CA2210966A1 (en) | 1996-08-01 |
| DK0805812T3 (da) | 2001-09-17 |
| AU694611B2 (en) | 1998-07-23 |
| EP0805812A1 (en) | 1997-11-12 |
| KR19980701780A (ko) | 1998-06-25 |
| WO1996022991A1 (en) | 1996-08-01 |
| JPH11501616A (ja) | 1999-02-09 |
| EP0805812B1 (en) | 2001-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3036560T3 (en) | Bicyclic substituted hexahydrobenz(e)isoindole alpha-1- adrenergic antagonists | |
| IL116405A0 (en) | Tricyclic substituted hexahydrobenz (e) isoindole alpha-1 adrenergic antagonists | |
| IE873548L (en) | Peptidylaminodiols | |
| MX9705313A (es) | Benzazepinas triciclicas antagonistas de la vasopresina. | |
| MY132229A (en) | Indole derivatives as 5-ht receptor antagonist | |
| RU2012110522A (ru) | Гипотензивная комбинация валсартана и блокатора кальциевых каналов | |
| CA2164689A1 (en) | NK-1 Receptor Antagonists and 5HT3 Receptor Antagonists for the Treatment of Emesis | |
| WO2002060392A3 (en) | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
| MX9705415A (es) | Antagonsitas de vasopresina triciclicos de benzazepina. | |
| AU6999796A (en) | Heterocyclic compounds as bradykinin antagonists | |
| CY2260B1 (en) | Benzopyranopyrrole and benzopyranopyridine alpha-1adrenergic compounds | |
| AU8534291A (en) | Renal-selective angiotensin ii antagonists for treatment of hypertension | |
| MX9708557A (es) | Nuevo uso farmacologico de los antagonistas del receptor aii. | |
| DE69819166D1 (de) | 8-substituierte-9h-1,3-dioxolo/4,5-h//2,3/benzodiazepin derivate als ampa/kainate-rezeptor-hemmer | |
| MY118704A (en) | Process for preparation of eprosartan | |
| GR3030506T3 (en) | 1-azaadamantane derivatives as 5-ht agonists or antagonists. | |
| RO115802B1 (ro) | Derivaţi ai acidului pirazol dihidrobenzofuranil propenoic, intermediar pentru prepararea acestora, compoziţii farmaceutice ale acestora şi metodă de tratament | |
| EP0804186A4 (en) | INDOLDITERPEN ALKALOIDS | |
| EP2140862A3 (en) | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | |
| AU3361693A (en) | Use of 5-HT4 receptor antagonists as medicaments for treating migraine | |
| BR9713682A (pt) | Compostos alfa - 1 adrenergicos de benzopiranopirrol e benzopiranopiridina | |
| MX9701220A (es) | Antagonistas de endotelina. | |
| CA2210631A1 (en) | Tricyclic benzazepine vasopressin antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |